

ADVENTRX PHARMACEUTICALS Inc. (San Diego, Calif.)

In an effort to focus on completing a strategic transaction with another company or otherwise secure financing, Adventrx reduced its full-time workforce of 14 employees to five executives and will discontinue all of its drug development activities and business operations. Since October 2008, the company has reduced its workforce by 55 percent.

ARIAD PHARMACEUTICALS Inc. (Cambridge, Mass.)

A. Collier Smyth, MD, who recently retired as Senior Vice President of Medical Strategy, Oncology at Bristol-Myers Squibb and led the company's oncology medical affairs in the US, was named to Ariad's Board of Directors.

ARIZONA CANCER CENTER (Tucson, Ariz.)

Andrew M. Yeager, MD, Director of the Blood and Marrow Transplantation Program at the Arizona Cancer Center and Professor of Medicine and Pediatrics at the University of Arizona College of Medicine, was appointed to the Peter and Paula Fasseas Endowed Chair for Excellence in Cancer Research at the Cancer Center. Dr. Yeager specializes in both pediatric and adult hematology and oncology and is one of the leading blood and marrow transplanters in the US.

ASSOCIATION OF COMMUNITY CANCER CENTERS (Rockville, Md.)

Luana Lamkin, RN, MPH, became President of the ACCC at its 35th Annual Meeting in March. Lamkin, an administrator for St. Luke's Mountain States Tumor Institute (MSTI) in Boise, Idaho, has served on the ACCC's Board of Directors since 2002. During her year-long tenure, she plans to draw attention to the impending professional workforce shortage in oncology, particularly in the area of oncology nursing.

AURORA HEALTH CARE (Milwaukee, Wis.)

The not-for-profit healthcare provider, which cares for more cancer patients than any other health system in Wisconsin, appointed **Joseph Mirro Jr., MD**, as its Vice President of Cancer Services. He was previously Executive Vice President (EVP) of Physician Relations and Domestic Affiliates at St. Jude Children's Research Hospital in Memphis, Tenn.

BIOGEN IDEC (Cambridge, Mass.)

Cecil B. Pickett, PhD, President, Research and Development (R&D), plans to retire but will remain on the Board of Directors. **Michael E. Lytton** was appointed as EVP, Business and Corporate Development. **Robert A. Hamm**, who had been EVP, Pharmaceutical Operations & Technology since 2007, was named Chief Operating Officer (COO). He replaces **Hans Peter Hasler**.

BRISTOL-MYERS SQUIBB Co. (New York, N.Y.)

Giovanni Caforio was named as Senior Vice President, Global and U.S. Oncology. Caforio was previously head of the US cancer unit.

CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS (Austin, Tex.)

William Gimson was named Executive Director of CPRIT by its Oversight Committee, a governing body comprised primarily of members

appointed by Texas state officials. Gimson recently retired as the COO of the Centers for Disease Control after 35 years of administrative service.

CHAMPIONS BIOTECHNOLOGY Inc. (Baltimore, Md.)

Citing an increased demand for its personalized oncology services, particularly by European oncologists, the company expanded its business with a UK subsidiary, Champions Biotechnology UK Ltd., and appointed **Guy Malchi** as General Manager. Malchi was formerly the Chief Executive Officer (CEO) of Optimata Ltd. The new subsidiary will also have a branch in Israel.

EXACT SCIENCES Corp. (Marlborough, Mass.)

The colon cancer test developer announced a new management team: **Kevin T. Conroy** is President and Chief Executive, and **Maneesh K. Arora** is Senior Vice President and Chief Financial Officer. Both Conroy and Arora held the same positions, respectively, at Third Wave Technologies Inc. **Jeffrey R. Luber** and **Charles R. Carelli Jr.**, who had been the company's President and Chief Executive, and Chief Financial Officer, respectively, resigned but will remain with the company through a transition period.

THE INTERNATIONAL MYELOMA FOUNDATION (North Hollywood, Calif.)

IMF's co-founder and Chairman, **Brian G.M. Durie, MD**, was recognized with the prestigious Waldenström's Award for lifetime achievement in myeloma at the XII International Myeloma Workshop in Washington, D.C. Dr. Durie, a practicing hematologist/oncologist, is National Director for Hematological Malignancies at Aptium Oncology, and is a myeloma specialist at Cedars-Sinai Outpatient Cancer Center in Los Angeles.

IU SIMON CANCER CENTER (Indianapolis, Ind.)

Patrick J. Loehrer Sr., MD, an internationally recognized researcher and specialist in testicular cancer, gastrointestinal cancer and thymoma, was named interim Director of the Indiana University Melvin and Bren Simon Cancer Center. He succeeds **Stephen Williams, MD**, the Cancer Center's late founding Director, who succumbed to cancer in February.

M. D. ANDERSON CANCER CENTER (Houston, Tex.)

Physicians and researchers from four Texas Medical Center institutions—the Texas Children's Cancer Center, the Children's Cancer Hospital at the University of Texas M. D. Anderson Cancer Center, the Methodist Hospital, and Baylor College of Medicine—have joined forces in the fight against a rare childhood eye cancer resulting in the Retinoblastoma Center of Houston. The Center will be the first of its kind in the Southwest and the only one in the nation using gene therapy in clinical trials to treat and potentially find a cure for retinoblastoma, which affects about 350 infants and children in the US annually.

NYU CANCER INSTITUTE (New York, N.Y.)

Michele Pagano, MD, was appointed Deputy Director of the NYU Cancer Institute at NYU Langone Medical Center. Dr. Pagano has led the NYU Cancer Institute's Growth Control Program since 2000. In his new role, he will work with the Center's senior leadership team to develop a

cohesive agenda for cancer research and therapy and to speed the translation of laboratory findings into more effective approaches to cancer prevention and treatment.

OSU COMPREHENSIVE CANCER CENTER (Columbus, Ohio)

Clara D. Bloomfield, MD, a Distinguished Professor at the Ohio State University Comprehensive Cancer Center and its former Director, will receive the 2009 David A. Karnofsky Memorial Award during ASCO's upcoming 45th Annual Meeting in Orlando, Fla. for her groundbreaking contributions to clinical research. Dr. Bloomfield is one of the first physician-scientists to suggest and demonstrate that adults with acute leukemia, including the elderly, could be cured with chemotherapy.

PFIZER Inc. (New York, N.Y.)

Elizabeth Barrett was named Regional President, US, for the Oncology Business Unit with responsibilities in sales, field operations, and marketing. An oncology industry veteran, Barrett was most recently Cephalon's Vice President & General Manager, Oncology Business. Her previous experience also includes managing Johnson & Johnson's (J&J) cancer therapeutics business and serving as Worldwide Vice President of Sales and Marketing for J&J's diagnostic oncology products company, Veridex LLC.

Pfizer also announced that **Martine J. George, MD, MSc**, was appointed Vice President of Medical Affairs for the Oncology Business Unit. Dr. George will be responsible for managing external relationships with cancer agencies, organizations and specialists around the world. She was previously Senior Vice President of Drug Development and Chief Medical Officer (CMO) at GPC Biotech Inc.

As part of a widespread research and commercial restructuring due to its Wyeth acquisition, which is expected to close during the third or fourth quarter of 2009, Pfizer said that oncology would comprise one of its nine diverse global healthcare businesses and would continue to be led by President **Garry Nicholson**.

PROTEOLIX Inc. (South San Francisco, Calif.)

John A. Scarlett, MD, was appointed as President and CEO. **Susan Molineaux, PhD**, who founded Proteolix in 2003, will transition from her position as CEO to serve as Chief Scientific Officer.

ROCHE HOLDING AG (Basel, Switzerland)

Roche and Genentech Inc. announced plans for a successful integration of the two companies on April 15 following the completion of the Swiss drug maker's purchase of the biotech pioneer for \$46.8 billion in late March.

Genentech's two top executives, Chairman and CEO **Art Levinson** and **Susan Desmond-Hellmann**, President of Product Development, will be leaving day-to-day operations of the company while its two top research scientists will be promoted to new posts. Levinson, who has led Genentech for 14 years, will be succeeded by **Pascal Soriot**, who has been responsible for commercial operations for Roche's pharma division. Levinson will become Chairman of a new Genentech Board of Directors and will lead the strategic integration of the two companies. He will also serve as an adviser to Genentech's Research and Early Development center. Desmond-Hellmann will leave her position by mid-year but will continue to work with Genentech as an adviser and as a member of Genentech's Scientific Resource Board.

Genentech's two top research scientists, **Richard Scheller**, currently Executive Vice President (EVP) of Research, and **Marc Tessier-Lavigne**, currently EVP of Research Drug Discovery, will both be promoted to new posts. Scheller was named head of Genentech's Research and Early

Development center and **Tessie-Lavigne** will succeed Scheller as EVP of Research and will also become Chief Scientific Officer. Genentech's current CMO **Hal Barron** will also stay on board and will become EVP, Head of Global Development, and CMO for the combined US organization.

Two other key executives, **David Ebersman, EVP and Chief Financial Officer**, and **Steve Juelsgaard, EVP and Chief Compliance Officer**, will both leave Genentech.

Roche plans to consolidate its US-based commercial operations at Genentech's South San Francisco campus, but maintain Research and Early Development as an independent center there and keep the Genentech name. Roche Chairman **Franz Humer** has said that a top priority of the merger will be to preserve Genentech's highly-regarded research culture. The organizational and leadership changes will take effect on May 1.

SYNTA PHARMACEUTICALS Corp. (Lexington, Mass.)

The company eliminated 90 positions based in Massachusetts, 41 percent of its workforce, in mid-March after a Phase 3 trial of its experimental metastatic melanoma drug, elesclomal, was suspended due to safety concerns. The reductions will allow the company to operate for about two more years relying on its current cash reserves and without the need for additional equity financing.

TRANSMOLECULAR Inc. (Cambridge, Mass.)

The privately-held biotech appointed **Robert Radie** as President and Chief Executive, and promoted **E. Michael Egan**, its former President and Chief Executive, to the position of Vice Chairman of the Board. Radie previously served as a full-time business development consultant for the company. He was EVP and Chief Business Officer at Prestwick Pharmaceuticals Inc. before joining TransMolecular.

UNIVERSITY OF CALIFORNIA, LOS ANGELES (Los Angeles, Calif.)

UCLA launched the new Institute of Urologic Oncology—a first-of-its-kind, patient-centered institute dedicated to developing leading-edge therapies for the treatment of kidney, bladder, testicular, and prostate cancers. **Arie Belldegrun, MD**, a Professor of Urology and a researcher at UCLA's Jonsson Comprehensive Cancer Center, will serve as Director. The genitourinary cancer institute's research and clinical model will follow a multidisciplinary, translational approach to care and targeted therapies, largely pioneered at UCLA, where the breast cancer drug Herceptin® was developed.

US ONCOLOGY (Houston, Tex.)

The cancer treatment and research network established US Oncology Clinical Development (USOCD), a full service contract research organization, formalizing many of the services that US Oncology Research has provided to pharmaceutical and biotechnology companies since 1999. US Oncology also announced that it was named to "Fortune Magazine's Most Admired Companies" list for 2009 for the fourth time. The company ranks third in the Health Care: Pharmacy and Other category.

YALE CANCER CENTER (New Haven, Conn.)

Thomas J. Lynch, MD, was named Director of the Yale Cancer Center and Physician-in-Chief of the new Smilow Cancer Hospital at Yale-New Haven, scheduled to open in October 2009. Dr. Lynch, a lung cancer expert, is Chief of Hematology/Oncology at Massachusetts General Hospital (MGH) Cancer Center and Director of the Center for Thoracic Cancers at MGH in Boston. **NIG**